| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/26/2011 | CA2814784A1 Soluble physiological chitosan formulations combined with platelet-rich plasma (prp) for tissue repair |
| 05/26/2011 | CA2793751A1 Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (hiv) |
| 05/26/2011 | CA2793749A1 Novel schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (hiv) |
| 05/26/2011 | CA2792198A1 Macrocyclic lactone derivatives for the treatment of cancer |
| 05/26/2011 | CA2781935A1 Pyridine-pyridinone derivatives, preparation and therapeutic use thereof |
| 05/26/2011 | CA2781698A1 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof |
| 05/26/2011 | CA2781669A1 Cyclodextrin-based polymers for therapeutic delivery |
| 05/26/2011 | CA2781580A1 Topical foam composition |
| 05/26/2011 | CA2781579A1 Topical foam composition |
| 05/26/2011 | CA2781550A1 Antimicrobial compositions containing free fatty acids |
| 05/26/2011 | CA2781547A1 Materials and methods useful for affecting tumor cell growth, migration and invasion |
| 05/26/2011 | CA2781434A1 Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases |
| 05/26/2011 | CA2781384A1 Biofilm disruptive compositions |
| 05/26/2011 | CA2781380A1 Quinazoline derivatives |
| 05/26/2011 | CA2781300A1 Methods and compositions for treating hedgehog-associated cancers |
| 05/26/2011 | CA2781287A1 Compounds and methods for kinase modulation, and indications therefor |
| 05/26/2011 | CA2781286A1 Oral formulation for dexlansoprazole |
| 05/26/2011 | CA2781277A1 Urinary triaosylceramide (gb3) as a marker of cardiac disease |
| 05/26/2011 | CA2781210A1 Methods and compositions for treating solid tumors and other malignancies |
| 05/26/2011 | CA2781194A1 Reducing inflammation using cell therapy |
| 05/26/2011 | CA2781139A1 Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions |
| 05/26/2011 | CA2781066A1 Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use |
| 05/26/2011 | CA2781063A1 Combination |
| 05/26/2011 | CA2781061A1 Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom |
| 05/26/2011 | CA2781044A1 Predictive markers for taxane responsiveness and methods of use thereof |
| 05/26/2011 | CA2781012A1 Inhalation solutions |
| 05/26/2011 | CA2780979A1 Methods and assays for the treatment of irritable bowel syndrome |
| 05/26/2011 | CA2780977A1 Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof |
| 05/26/2011 | CA2780955A1 Fluorinated oxa or thia heteroarylalkylsulfide derivatives for combating invertebrate pests |
| 05/26/2011 | CA2780930A1 Method for production of f-18 labeled glutamic acid derivatives |
| 05/26/2011 | CA2780912A1 Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders |
| 05/26/2011 | CA2780840A1 Iodine-labeled homoglutamic acid and glutamic acid derivatives |
| 05/26/2011 | CA2780779A1 Acid salt forms of polymer-drug conjugates and alkoxylation methods |
| 05/26/2011 | CA2780777A1 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| 05/26/2011 | CA2780586A1 Combination therapy for treating or preventing an inflammatory skin disorder |
| 05/26/2011 | CA2780463A1 Imidazo-pyrazoles as gpr119 inhibitors |
| 05/26/2011 | CA2780333A1 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| 05/26/2011 | CA2780287A1 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| 05/26/2011 | CA2780150A1 Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors |
| 05/26/2011 | CA2779937A1 Pharmaceutical composition for the treatment of bladder disorders |
| 05/26/2011 | CA2779860A1 Methods and compositions for the treatment of psychotic disorders through the identification of the sult4a1-1 haplotype |
| 05/26/2011 | CA2779563A1 Amidoacetonitrile compounds having pesticical activity |
| 05/26/2011 | CA2779490A1 Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
| 05/26/2011 | CA2778867A1 Substituted pyrrolidine-2-carboxamides |
| 05/26/2011 | CA2778432A1 Parenteral formulations of gemcitabine derivatives |
| 05/26/2011 | CA2778301A1 Compositions for treating centrally mediated nausea and vomiting |
| 05/26/2011 | CA2778206A1 Heterocyclic antiviral compounds |
| 05/26/2011 | CA2777719A1 Apremilast for the treatment of sarcoidosis |
| 05/26/2011 | CA2776855A1 Pharmaceutical composition comprising propofol |
| 05/26/2011 | CA2776849A1 Novel heterocyclic acrylamides and their use as pharmaceuticals |
| 05/26/2011 | CA2774868A1 Novel arylated camphenes, processes for their preparation and uses thereof |
| 05/26/2011 | CA2773409A1 Bicyclic compounds as .alpha.4.beta.2 nicotinic acetylcholine receptor ligands |
| 05/26/2011 | CA2689725A1 Polyol based-bioceramic composites |
| 05/25/2011 | EP2325651A2 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 05/25/2011 | EP2325315A1 Compositions and methods for inhibiting expression of huntingtin gene |
| 05/25/2011 | EP2325314A2 Targeting opposite strand replication intermediates of single-stranded viruses by RNAI |
| 05/25/2011 | EP2325313A2 pRNA chimera |
| 05/25/2011 | EP2325302A1 Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE) |
| 05/25/2011 | EP2325301A1 Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE) |
| 05/25/2011 | EP2325300A1 Desaturase genes and uses thereof |
| 05/25/2011 | EP2325278A1 Polycationic viscoelastic compositions |
| 05/25/2011 | EP2325218A1 Antimicrobial copolymers and uses thereof |
| 05/25/2011 | EP2325196A1 Replikin peptides and uses thereof |
| 05/25/2011 | EP2325193A2 Methods and compositions for therapeutic use of RNA interference |
| 05/25/2011 | EP2325187A1 The hydrosulfate of prasugrel, its pharmaceutical combination and uses thereof |
| 05/25/2011 | EP2325186A2 Fused Bicyclic mTor Inhibitors |
| 05/25/2011 | EP2325185A1 Plk inhibitor |
| 05/25/2011 | EP2325184A1 Azaindoles useful as inhibitors of protein kinases |
| 05/25/2011 | EP2325183A1 4-(2-Furoyl) Aminopiperidine compound useful as therapeutic agent for itching |
| 05/25/2011 | EP2325182A1 Bicyclic compounds and use as antidiabetics |
| 05/25/2011 | EP2325181A1 Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient |
| 05/25/2011 | EP2325180A1 Chiral CIS-imidazolines |
| 05/25/2011 | EP2325179A1 Glycosidase ihhibitors and preparation thereof |
| 05/25/2011 | EP2325177A1 Crystalline base of escitalopram |
| 05/25/2011 | EP2325175A1 2,4-diaminopyrimidine compound |
| 05/25/2011 | EP2325174A1 Sigma receptor inhibitors |
| 05/25/2011 | EP2325172A1 Co-crystals of celecoxib and L-proline |
| 05/25/2011 | EP2325171A1 Quinoline derivatives for treating retinal diseases |
| 05/25/2011 | EP2325169A2 Lisofylline analogues and their pharmeacuetical uses |
| 05/25/2011 | EP2325163A1 Platinum complex and medical compound containing same |
| 05/25/2011 | EP2325159A1 Novel salts of rasagiline |
| 05/25/2011 | EP2324863A1 Method for producing artificial skin |
| 05/25/2011 | EP2324861A1 In vivo use of water absorbent polymers |
| 05/25/2011 | EP2324855A1 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 05/25/2011 | EP2324854A1 Drug sustained release agent, adsorbent, functional food, mask, and adsorptive sheet |
| 05/25/2011 | EP2324852A1 Therapeutic or prophylactic agent for generalized pain syndrome |
| 05/25/2011 | EP2324851A1 Methods of administering anti-TNFalpha antibodies |
| 05/25/2011 | EP2324843A1 Use of TNF-alpha inhibitors for treating nerve root injury |
| 05/25/2011 | EP2324841A1 Use of a traditional chinese medicinal composition for preparing medicine for promoting bone marrow-derived mesenchymal stem cell survival in vivo and cardiac muscle differentiation |
| 05/25/2011 | EP2324838A1 Compositions Comprising Dimethyl Sulfoxide (DMSO) |
| 05/25/2011 | EP2324837A1 Synthetic lipophilic inositol glycans for treatment of glucose-metabolism disorders |
| 05/25/2011 | EP2324836A1 Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino¨benzoic acid |
| 05/25/2011 | EP2324835A2 Composition of dialysis liquid comprising crystallisation inhibitor substances |
| 05/25/2011 | EP2324834A2 Methods of Increasing Endogenous Erythropoietin (EPO) |
| 05/25/2011 | EP2324833A1 Film preparation containing loperamide hydrochloride |
| 05/25/2011 | EP2324832A1 Nutritional supplement while taking hormonal contraceptives |
| 05/25/2011 | EP2324831A1 Methods of administering pirfenidone therapy |
| 05/25/2011 | EP2324830A1 Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage |
| 05/25/2011 | EP2324829A1 Therapeutic inhibitors of vascular smooth muscle cells |
| 05/25/2011 | EP2324828A1 Treatment for neurodegenerative conditions |